These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 19669256)

  • 61. Markov models in medical decision making: a practical guide.
    Sonnenberg FA; Beck JR
    Med Decis Making; 1993; 13(4):322-38. PubMed ID: 8246705
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.
    Wong JB; Koff RS; Tinè F; Pauker SG
    Ann Intern Med; 1995 May; 122(9):664-75. PubMed ID: 7702228
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal.
    Dusheiko GM; Roberts JA
    Hepatology; 1995 Dec; 22(6):1863-73. PubMed ID: 7489999
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The economics of treating chronic hepatitis B in Asia.
    Dan YY; Aung MO; Lim SG
    Hepatol Int; 2008 Sep; 2(3):284-95. PubMed ID: 19669256
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Entecavir for the treatment of chronic hepatitis B infection.
    Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
    Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Telbivudine for the treatment of chronic hepatitis B infection.
    Hartwell D; Jones J; Harris P; Cooper K
    Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
    Jones J; Colquitt J; Shepherd J; Harris P; Cooper K
    Health Technol Assess; 2010 May; 14 Suppl 1():23-9. PubMed ID: 20507800
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.
    Crossan C; Tsochatzis EA; Longworth L; Gurusamy K; Davidson B; Rodríguez-Perálvarez M; Mantzoukis K; O'Brien J; Thalassinos E; Papastergiou V; Burroughs A
    Health Technol Assess; 2015 Jan; 19(9):1-409, v-vi. PubMed ID: 25633908
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence.
    Sun X; Qin WX; Li YP; Jiang XH
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1369-77. PubMed ID: 17716343
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
    Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.
    Han SH
    Drugs; 2006; 66(14):1831-51. PubMed ID: 17040114
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Chronic hepatitis B virus infection in Asian countries.
    Merican I; Guan R; Amarapuka D; Alexander MJ; Chutaputti A; Chien RN; Hasnian SS; Leung N; Lesmana L; Phiet PH; Sjalfoellah Noer HM; Sollano J; Sun HS; Xu DZ
    J Gastroenterol Hepatol; 2000 Dec; 15(12):1356-61. PubMed ID: 11197043
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B.
    Wiens A; Venson R; Correr CJ; Pontarolo R
    Braz J Infect Dis; 2011; 15(3):225-30. PubMed ID: 21670922
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Management of viral hepatitis B.
    Pramoolsinsup C
    J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.